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T20-resistant strainsein expressed in Escherichia coli, has been previously reported to inhibit HIV-1
membrane fusion at low nanomolar level. Here we report that HR212 is effective in blocking laboratory strain
HIV-1IIIB entry and replication with EC50 values of 3.92±0.62 and 6.59±1.74 nM, respectively, and inhibiting
infection by clinic isolate HIV-1KM018 with EC50 values of 44.44±10.20 nM, as well as suppressing HIV-1-
induced cytopathic effect with an EC50 value of 3.04±1.20 nM. It also inhibited HIV-2ROD and HIV-2CBL-20
entry and replication in the µM range. Notably, HR212 was highly effective against T20-resistant strains with
EC50 values ranging from 5.09 to 7.75 nM. Unlike T20, HR212 showed stability sufﬁcient to inhibit syncytia
formation in a time-of-addition assay, and was insensitive to proteinase K digestion. These results suggest
that HR212 has great potential to be further developed as novel HIV-1 fusion inhibitor for treatment of HIV/
AIDS patients, particularly for those infected by T20-resistant variants.
© 2008 Elsevier Inc. All rights reserved.Introduction
Membrane fusion between human immunodeﬁciency virus (HIV) and
target cells represents an attractive focus for the development of new
antiviral drugs. In past decades, several peptides thatmimic the sequence
of the N-terminal heptad-repeat region (HR1) or the C-terminal heptad-
repeat region (HR2) of HIV-1 transmembrane subunit gp41 have been
found topotently inhibitHIV-1 fromentering intohost cells (Rusconi et al.,
2007). A good example is enfuvirtide (T20), a 36-amino acid synthetic
peptide derived from the heptad-repeat 2 (HR2) region of gp41, which
inhibitedHIV-1-mediatedmembrane fusion at the nanomolar level (Wild
et al., 1994). However, although T20 is highly effective in vitro, a dose of
nearly 200mg/daybysubcutaneous injection is required tomaintain anti-
HIV-1 efﬁcacy in HIV/AIDS patients. In addition, one of the major
limitations of T20 as an anti-HIV-1 therapy is the difﬁculty of peptide
synthesis. This results in lower supply and higher production costs in
comparison to other anti-HIV drugs (Tashima and Carpenter, 2003).Center for Molecular Virology,
hina. Y.-T. Zheng, Laboratory of
Zoology, Chinese Academy of
ngyt@mail.kiz.ac.cn
l rights reserved.To address these limitations and improve the stability and potency
of T20, we previously designed two HIV-1 fusion inhibitory proteins,
HR121 formed by linking HR1 (N34) to the C terminus of HR1–HR2
and HR212 formed by linking HR2 (C34) to the N terminus of HR1–
HR2 (HR212). These two proteins have been expressed in Escherichia
coli as soluble proteins. When tested in a luciferase reporter virus,
both HR212 and HR121 potently inhibited HIV-1 envelope glycopro-
tein-mediated virus-cell fusion, with the IC50 values of 2.8 nM and
16.2 nM, respectively (Ni et al., 2005). However, compared to HR121,
HR212 (C34–N34–C34) has been shown to be more soluble and easily
puriﬁed with noticeably more potent inhibitory activity. Therefore, in
the present study, the anti-HIV activities of HR212 were investigated
in vitro, and we found that HR212 signiﬁcantly inhibited entry and
replication of laboratory and clinical HIV-1 strains.
Results
Anti-HIV activities of HR212
The antiviral activities of HR212 are summarized in Table 1.
Designed as an HIV-1 fusion inhibitor, HR212 displayed anti-HIV
activities similar to, but more signiﬁcant than, T20 on cell-to-cell
fusion. Speciﬁcally, the EC50s of HR212 and T20 against HIV-1IIIB isolate
entry were 3.92±0.62 nM and 2.38±1.12 nM, respectively (Fig. 1A).
Table 1
Summary of anti-HIV activities of HR212
Compounds Cells HIV strains Assays EC50 (nM)
HR212 C8166 HIV-1IIIB/H9 Co-cultivation 3.92±0.62
HIV-2CBL-20/H9 Co-cultivation 103±15
HIV-2ROD/H9 Co-cultivation 5377±578
C8166 HIV-1IIIB Syncytia 6.59±1.74
HIV-2CBL-20 Syncytia 170±57
HIV-2ROD Syncytia 5927±1037
PBMC HIV-1KM018 P24 44.44±10.20
MT4 HIV-1IIIB MTT 3.04±1.20
H9/HIV-1IIIB HIV-1IIIB P24 N14500
T20 C8166 HIV-1IIIB/H9 Co-cultivation 2.38±1.12
HIV-2CBL-20/H9 Co-cultivation 260±44
HIV-2ROD/H9 Co-cultivation 16337±2095
C8166 HIV-1IIIB Syncytia 22.28±0.68
HIV-2CBL-20 Syncytia 3383±350
HIV-2ROD Syncytia 24807±2986
PBMC HIV-1KM018 P24 17.28±1.60
MT4 HIV-1IIIB MTT 25.45±2.08
H9/HIV-1IIIB HIV-1IIIB P24 N14500
AZT C8166 HIV-1IIIB Syncytia 11.45±5.87
PBMC HIV-1KM018 P24 9.17±2.38
MT4 HIV-1IIIB MTT 13.23±0.08
IDV H9/HIV-1IIIB HIV-1IIIB P24 760±290
EC50 is the effective concentration that inhibits 50% of viral production. The data are
representative of three independent experiments.
Fig. 1. Inhibitory activities of HR212 on blocking fusion. The cell-to-cell fusion between
normal C8166 cells and HIV-1IIIB (A), HIV-2CBL-20 (B) or HIV-2ROD (C) infected H9 cells
was assessed by syncytia formation observed under inverted microscope.
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μM range. The EC50s of HR212 against HIV-2CBL-20 and HIV-2ROD were
approximately 3-fold lower than those of T20 (Figs. 1B, C). Impor-
tantly, cytotoxicity of HR212 was not detectable against the C8166,
MT-4, MT-2, H9, PBMC or H9/HIV-1IIIB cell lines (CC50sN145 μM, data
not shown).
The effects of HR212 on viral replication in acute infection were
observed by the reduction of syncytia formation. HR212 blocked 50%
of the syncytia formation induced by HIV-1IIIB at 6.59±1.74 nM with
the corresponding data of T20 at 22.28±0.68 nM. The EC50 of HR212
was approximately 3-fold lower than that of T20 in anti-HIV-1
activities in acute infection (Fig. 2A). Similarly, the EC50s of HR212
required to block syncytia formation induced by HIV-2ROD and HIV-
2CBL-20 infection were about 5- and 20-fold lower than those of T20
(Figs. 2B, C).
HR212 suppression of viral replication was also assessed by
measuring the expression of HIV-1 p24 antigen. HR212 dramatically
reduced p24 production in low-passage clinically isolated virus
HIV-1KM018 replication with an EC50 value of 44.44±10.20 nM,
about 2-fold higher than that of T20 (Fig. 2D). Neither HR212 nor
T20 showed any efﬁcacy on p24 replication in HIV-1 chronically
infected H9 cells, as indicated by their EC50 values, which were
above 14.5 μM.
In MT-4 cells infected with HIVIIIB, HR212 exhibited protective
activity against HIV-1-induced cytopathic effect with an EC50 value
about 8-fold lower than that of T20. The EC50 values of HR212 and T20
were 3.04±1.20 nM and 25.45±2.08 nM, respectively (Fig. 3).
The sensitivity of HR212 to T20-resistant HIV strains
To determine whether HR212 is able to inhibit replication of
HIV-1 strains resistant to T20, one T20-sensitive and three T20-
resistant strains were tested in our experiments. While both
HR212 and T20 were active against the T20-sensitive strain,
pNL4-3gp41 (36G) N42S, only HR212 showed strong inhibitory activities
against all three T20-resistant strains with EC50 values in the nM
range: pNL4-3gp41 (36G) V38A, N42D, pNL4-3gp41 (36G) V38E, N42D and
pNL4-3gp41 (36G) V38A, N42T. In contrast, T20 failed to do so, even
with concentrations at least 100-fold or higher (Table 2 and Fig. 4).Stability of HR212 in medium
After HIV-1IIIB infection of C8166 cells, HR212 added at various
times showed antiviral activity similar toT20 in blocking both syncytia
formation and p24 antigen production (Figs. 5A, B). Since HR212
blocked HIV-1 replication at an early stage (about 1 h earlier), this
result demonstrated that HR212 acts only as an HIV-1 entry inhibitor.
However, in a parallel assay, C8166 cells were pretreated with
peptides at various times. In this case, T20 could neither completely
inhibit HIV-1 from inducing syncytia formation nor block HIV-1 p24
Fig. 2. Inhibitory activities of HR212 on blocking HIV-1 replication in acute infection. Inhibition of HIV-1IIIB (A), HIV-2ROD (B) or HIV-2CBL-20 (C) replication in C8166 cells was assessed
by syncytia formation observed under invertedmicroscope. Inhibition of HIV-1KM018 (D) replication in PBMCwas assessed by p24 antigen expression in the culture supernatant using
ELISA.
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rapidly. Conversely, HR212 maintained consistent anti-HIV activity
(Figs. 5C, D).Fig. 3. Protection of HR212 fromHIV-1-induced lytic effects. The protection of HR212 (A) and
infected MT-4 cells.In order to explain this difference, a direct ELISAwas performed. In
the RPMI-1640 medium without cells, the concentration of residual
HR212 shared a curve similar to T20 (Fig. 6A). However, in the cultureT20 (B) fromHIV-1-induced lytic effects was determined in mock-infected and HIV-1IIIB-
Table 2
Inhibition activities of HR212 on T20-resistant viruses
Virus Phenotypea EC50 (mean±SD, nM)
HR212 T20
pNL4-3gp41 (36G) N42S S 5.79±1.22 36.26±5.76
pNL4-3gp41 (36G) V38A, N42D R 6.42±1.36 640.44±159.92
pNL4-3gp41 (36G) V38E, N42S R 7.75±0.72 N1450
pNL4-3gp41 (36G) V38A, N42T R 5.09±0.34 N1450
a Sensitive (S) or resistant (R) to T20.
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up to 72 h, while detectable T20 was only 18.48% at 16 h (Fig. 6B),
indicating that HR212 could either be degraded or absorbed by cells at
a much slower rate than T20. In the culture supernatant of H9 and
PBMC cells, this tendency was replicated (Figs. 6C, D).
Sensitivity of HR212 to proteinase K
There were signiﬁcant differences in the biophysical and anti-HIV
activities between HR212 and T20; particularly, HR212 showed
stronger antiviral potency than T20. Thenwe compared the sensitivity
of HR212 and T20 to proteinase K. When incubated with 2 μg/ml of
proteinase K for 4 h, HR212 showed little change in ELISA detection
(Fig. 7A), and its antiviral potency remained ﬁrmly stable (Fig. 7B). On
the contrary, even if incubated with 2 μg/ml of proteinase K for only
5 min, T20 was undetectable, and its antiviral activity was completely
lost (data not shown). Thenwe used 20 ng/ml of proteinase K to digestFig. 4. Inhibitory activities of HR212 on the replication of T20-resistant strains. Inhibition of
pNL4-3gp41 (36G) V38A, N42T (D) replication in C8166 cells was assessed by syncytia formationT20, a 100-fold concentration lower than that of HR212, and found
that detectable T20 decreased quickly (Fig. 7A) and that its antiviral
potency also decreased rapidly andwas lost at 45min or later (Fig. 7B).
These results indicated that HR212 was much more resistant to
proteinase K than T20.
Discussion
In the present research, we conﬁrmed the anti-HIV potency of
HR212 in blocking both virus-mediated cell-to-cell transmission and
virus-to-cell transmission and its antiviral activity was not attributed
to the cytotoxicity and cytostasis. The inhibitory activity of HR212 was
speciﬁc for HIV-1 because HR212 required a concentration 1000-fold
higher to achieve an antiviral effect similar to its efﬁcacy with HIV-1.
The speciﬁcity of HR212 against HIV-1 may be ascribed to the
difference in the corresponding regions of HIV-1 and HIV-2 envelope
glycoproteins (Wild et al., 1994; Center et al., 1997).
Notably, in the studies of all three strains of HIV (HIV-1IIIB, HIV-2ROD
and HIV-2CBL-20), there was little difference in the EC50 value of HR212
between the blocking of cell-to-cell fusion and the blocking of viral
replication. On the other hand, the EC50 value of T20 in blocking cell–cell
fusionwas 10-fold lower than that in blocking viral replication (Table 1),
which is consistent with a previous report (Wild et al., 1994). The
different potencies of HR212 and T20 in cell-to-cell fusion and virus-to-
cell fusion assays might be a result of the disparate stabilities between
these two peptides. For example, in the cell-to-cell fusion assay, HR212
and T20 were only co-cultured with cells for 6 h, while in the virus-to-pNL4-3gp41 (36G) N42S (A), pNL4-3gp41 (36G) V38A, N42D (B), pNL4-3gp41 (36G) V38E, N42S (C), or
observed under inverted microscope.
Fig. 5. Time-of-addition assays. (1) Cells were pretreated with peptides for 2 h and washed; inhibition of viral replication and syncytia formation (A) and p24 antigen production (B)
was assessed at 72 h post-infection. (2) Cells were pretreated with peptides at different times; inhibition of syncytia formation (C) and p24 antigen production (D) was measured at
72 h post-incubation.
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conditions, T20 could have either hydrolyzed over time or could have
been absorbed by cells more quickly, thus losing its anti-HIV activities
earlier than HR212. To achieve effects similar to those of HR212, the
concentration of T20 needed to be higher.
Several reports found that T20 did not appear to interfere with the
activities of cytochrome P450, probably because it is a peptide and
easily hydrolyzed in the body (Zhang et al., 2004; Ruxrungtham et al.,
2004). Also, in some studies investigating the pharmacokinetics of
T20, it was found that its terminal half-life ranges from 4.35 h to 4.74 h
for a subcutaneous dose of 180 mg in the sera of HIV/AIDS patients
(Boyd et al., 2003; Stocker et al., 2006). These results agreewith and, in
part, explain the depletion of T20 in culture medium that we
observed. HR212 (C34–N34–C34) consists of two HR2 segments and
one HR1 segment and shows a salient α-helix character by CD
spectrometry (Ni et al., 2005). However, T20 is a 36-amino acid
synthetic peptide derived HR2 region of gp41 and is observed to be an
unordered formation (Liu et al., 2005; Kliger and Shai, 2000).
Therefore, T20 might be more easily hydrolyzed by proteolytic
enzymes secreted by cells than HR212. Even if HR212 is degraded
into peptides, some of them might contain HR2 or HR1 sequences,
which could still inhibit HIV entry into host cells.
In several clinical studies, T20 could quickly induce drug-resistant
strains (Baldwin et al., 2003, 2004). Another peptide derived fromHR2
region, C34, is more effective than T20 against HIV-1, especially T20-resistant strains. However, C34 is less soluble in aqueous media than
T20, which might limit C34 from further development as a drug (Chan
et al., 1997). Three molecules of HR212s form a stable six-helix bundle
with three free HR2 (C34) exposed, which function like C34, but are
more soluble than C34 in physiologic solutions. HR212 showed strong
inhibitory activities against all four T20-resistant strains with EC50
values in the nM range (Table 2), suggesting that HR212 can be further
developed as an alternative fusion inhibitor for treatment of patients
with HIV-1/AIDS, in particular those infected with T20-resistant
variants. It is alsoworth noting that HR212was expressed in E. coli as a
soluble protein, demonstrating that it could be easily puriﬁed at low
production cost (Ni et al., 2005).
In conclusion, HR212 signiﬁcantly inhibited entry and replication of
laboratory and clinical HIV-1 strains. In particular, it could potently
block replication of T20-resistant strains. Furthermore, HR212 is more
stable in the cell culture supernatants and less sensitive to proteolysis
by proteinase K than T20. Thus, HR212 is a promising therapeutic
candidate against HIV-1 strains, particularly the T20-resistant variants.
Materials and methods
Reagents and chemicals
HR212 protein was prepared and puriﬁed as previously reported
(Ni et al., 2005). Enfuvirtide (T20) was purchased from Roche
Fig. 6. Stability of HR212 inmedium. The residual peptides in RPMI1640 (A) and in the culture supernatants of C8166 cells (B), H9 cells (C) and PBMC cells (D) were assessed by a direct
ELISA at different times.
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medium, sterilized by 0.22 μm ﬁltration and stored in aliquots at
−20 °C. MTT, zidovudine (AZT, 3′-azido-3′-deoxythymidine), Fc-
speciﬁc anti-mouse IgG, phosphonoformate (PFA) and horseradish
peroxidase (HRP)-labeled goat anti-rabbit IgG were purchased from
Sigma. Indinavir (IDV) was purchased from Glaxo Wellcome. P5F1, a
monoclonal antibody (mAb) to HIV-1 p24, rabbit polyclonal anti-p24
serum (Liu et al., 2007), and rabbit polyclonal anti-HR212 antibody
were prepared by our laboratory.
Cell lines and viruses
Human T lymphocyte H9, C8166, MT2, MT4 cells, human embryo
kidney 293 cells, and human epithelial HeLa cells were kindly donated
by the Medical Research Council, AIDS Research Project (UK).
Chronically infected H9 cells (H9/HIV-1IIIB, H9/HIV-2CBL-20, H9/HIV-
2ROD) were cultured by our laboratory. Cell lines were maintained in
RPMI-1640 supplemented with 10% heat-inactivated fetal calf serum
(Gibco). Peripheral blood mononuclear cells (PBMC) were isolated
from healthy donors (Kunming Blood Center, Yunnan) and incubated
in complete medium containing 5 ng/ml phytohemagglutinin (PHA)
(Sigma) and 50 U/ml human recombinant IL-2 (Sigma) for 3 days prior
to use for antiviral assays. The laboratory-derived viruses HIV-1IIIB,
HIV-2CBL-20, and HIV-2ROD, as well as the T20-resistant strains pNL4-
3gp41 (36G) N42 S, pNL4-3gp41 (36G) V38A, N42D, pNL4-3gp41 (36G) V38E, N42D,
and pNL4-3gp41 (36G) V38A, N42T were obtained through the NIH AIDS
Research and Reference Reagent Program (USA). The HIV-1 clinically
isolated strain HIV-1KM018 was isolated and cultured by our laboratoryfrom a Yunnan HIV/AIDS patient as described (Zhang et al., 2005). The
50% HIV tissue culture infectious doses (TCID50) were determined and
calculated by the Reed and Muench method. Viruses were stored at
−70 °C in aliquots.
Cytotoxicity assays
The cytotoxicities of HR212 or T20 on H9, C8166, MT2, MT4,
PBMC, 293, and HeLa cells were assessed by MTT colorimetric assay
as described previously (Wang et al., 2002). Brieﬂy, 100 μl of 4×104
cell suspension (5×105 for PBMC and 2×104 for HeLa) was seeded on
a 96-well microtiter plate, and a 100 μl compound solution at
different concentrations was added and incubated at 37 °C in a
humidiﬁed atmosphere of 5% CO2 for 72 h. Discarded 100 μl
supernatant in a 20 μl MTT solution (5 mg/ml in PBS) was added to
each well, followed by incubation at 37 °C for 4 h; then 100 μl of 50%
DMF–20% SDS was added. After the formazum was dissolved
completely, the plates were read on a Bio-Tek ELx 800 ELISA reader
at 595/630 nm. The cytotoxic concentration that caused the reduction
of viable cells by 50% (CC50) was calculated from the dose response
curve.
Cell-to-cell fusion inhibition assay
In the presence or absence of 100 μl of various concentrations of
HR212 or T20, 6×104 of C8166 cells (50 μl) were co-cultured with
2×104 of H9/HIV-1IIIB, H9/HIV-2ROD or H9/HIV-2CBL-20 cells (50 μl) at
37 °C in a humidiﬁed atmosphere of 5% CO2. After 6 h incubation, the
Fig. 7. Proteinase K sensitivity of HR212. Digested by proteinase K at different times, the
residual HR212 or T20 was assessed by a direct ELISA (A), and the remaining antiviral
potency of HR212 or T20 was assessed by cell-to-cell fusion inhibitory assay (B).
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inverted microscope; 50% effective concentration to blocking syncytia
formation (EC50) was calculated (Wang et al., 2004).
Assays for antiviral activity of peptides against acute and chronic HIV-1
infection
The inhibitory activities of HR212 or T20 against the laboratory-
derived HIV-1, HIV-2 isolates and the T20-resistant strains were
determined as previously described (Wang et al., 2002). Brieﬂy, in the
presence or absence of 100 μl of various concentrations of HR212 or
T20, 4×104 of C8166 cells (50 μl) were infected with different HIV
isolates (50 μl) at a multiplicity of infection (M.O.I.) of 0.03. AZT was
used as positive control. Then, the plates were incubated in a
humidiﬁed incubator at 37 °C and 5% CO2. After 3 days of culture,
the percentage inhibition of syncytia formation was scored and EC50
was calculated.
In a similar way, the compounds were tested against the clinically
isolated strain HIV-1KM018 in PBMC and chronically infected H9 cells
(H9/HIV-1IIIB). After 7 days (HIV-1KM018) or 3 days (H9/HIV-1IIIB) of
culture, the cell-free supernatants were collected and inactivated by
5% Triton X-100, and the level of p24 was measured by p24 antigen
capture ELISA (Zhang et al., 2005).
Assay for inhibitory activity of peptides on HIV-1-induced cytopathic
effect
HR212 or T20-medaited protection of MT-4 cells from HIV-1-
induced cytopathic effect was assessed. Brieﬂy, 4×104 of MT-4 cells
(100 μl) uninfected or infected by HIV-1 at 0.03 M.O.I. were culturedwith 100 μl of a peptide at different concentrations. After 7 days of
incubation at 37 °C, cell viability was determined by MTT assay
(Pauwels et al., 1988).
Time-of-addition assays
4×104 of C8166 cells (100 μl) were pre-infected with HIV-1IIIB
(50 μl, M.O.I.=0.03). 50 μl of HR212 (40 μg/ml) or T20 (40 μg/ml) was
added at different times after virus absorption; then the correspond-
ing compound was removed by washing cells 3 times after 2 h
incubation. After 3 days of culture, the syncytia numbers and p24
antigen in each well were measured and percentages of inhibition
were calculated (Snoeck et al., 2002).
In another assay, 4×104 of C8166 cells (100 μl) were pretreated
with 50 μl of HR212 (40 μg/ml) or T20 (40 μg/ml), then 50 μl of HIV-1IIIB
(M.O.I.=0.03) was added at different times and incubated for 3 days.
The inhibition of syncytia numbers and p24 antigen was calculated.
ELISA detection of the remaining compounds in the culture medium
100 μl of 4×104 C8166 cell suspension (5×105 for PBMC or 1×105
for H9) was cultured with 50 μl of HR212 (40 μg/ml) or T20 (40 μg/ml).
The cell-free supernatants were collected at different times to
estimate the residual compound concentrations. RPMI 1640 medium
treated with the same concentration of HR212 or T20 was used as
negative control. The residual HR212 or T20 in culture medium was
measured using a direct ELISA assay. Brieﬂy, polystyrene plates were
coated with the culture supernatant diluted 10 times in coating buffer
overnight at 37 °C. The plates were then incubated with 1:1000 rabbit
anti-HR212 antibody, followed by incubation with 1:5000 HRP-
labeled goat anti-rabbit IgG, and OPD substrate was added into the
wells. The optical density of the plates was read on Bio-Tek ELx800
ELISA reader at 490 nm/630 nm.
Proteinase K digestion experiments
To test proteinase K sensitivity of HR212 or T20, 40 μg/ml of HR212
or T20 dissolved in PBS was incubated with 2 μg/ml or 20 ng/ml of
proteinase K at 37 °C. At different times, the samples were collected
and heated at 95 °C for 10 min to inactive proteinase K. Then, residual
concentrations in the collected samples were detected by an ELISA
assay as mentioned above. In the alternative, the remaining antiviral
activities were tested by a cell-to-cell fusion inhibitory assay.
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